Healio8 小时
FDA approves subcutaneous Merilog for glycemic control in diabetes
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
Neurology Advisor16 小时
Study Finds Exenatide Not Beneficial for Parkinson Disease
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
pharmaphorum17 小时
EU approves CSL's once-monthly HAE drug Andembry
CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...
Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA
Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by ...
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
PMLiVE18 小时
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...
Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe ...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...